EGFR G719C

CI-VAR-00001793Explore in graph →NP_005219.2:p.Gly719CysNM_005228.4:c.2155G>TClinVar 16611 CIViC 998 rs28929495

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
EGFR G719C AND EGFR E709A	Erlotinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID6039 The E709A+G719C double mutation was found in an 80-year-old female never smoker with advanced adenocarcinoma of the lung with acinar and BAC characteristics. Erlotinib was given at the starting dose o… (full text at CIViC) PMID 21841502 · De Pas et al., 2011 · Open in CIViC	civic
Lung Squamous Cell Carcinoma1
EGFR G719C	Cisplatin + Nab-paclitaxel + SintilimabCombination	Predictive	C	Supports Sensitivity Response	3	submitted	EID13096 A patient with stage IV lung squamous cell carcinoma harboring an EGFR G719C mutation and high PD-L1 expression (tumor proportion score of 90%) experienced disease progression after 1.5 months of afat…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
16611	Pathogenic; drug response	no assertion criteria provided	0	Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, somatic; Non-small cell lung carcinoma	somatic	2	Nov 23, 2009	clinvar